Literature DB >> 8418839

Conformational changes in chicken thyroid hormone receptor alpha 1 induced by binding to ligand or to DNA.

J H Toney1, L Wu, A E Summerfield, G Sanyal, B M Forman, J Zhu, H H Samuels.   

Abstract

A classic model of steroid/thyroid hormone receptor activation postulates that a conformational change or "transformation" occurs upon ligand binding as a first step toward regulation of gene transcription. In order to test this model, physical studies have been carried out using purified full-length chicken thyroid hormone receptor alpha 1 (cT3R-alpha 1) expressed in Escherichia coli. Circular dichroism spectroscopic studies reveal that cT3R-alpha 1 adopts a different conformation upon specific binding to a cognate ligand triiodothyroacetic acid as well as to a thyroid hormone response element, an idealized inverted repeat AGGTCA TGACCT. These results suggest that cT3R-alpha 1 may adopt distinct conformations whether free or bound to ligand or to DNA. These states may reflect the changes in the conformation of steroid/thyroid hormone receptors in the signal transduction pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418839     DOI: 10.1021/bi00052a001

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  18 in total

1.  Mechanistic principles in NR box-dependent interaction between nuclear hormone receptors and the coactivator TIF2.

Authors:  J Leers; E Treuter; J A Gustafsson
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

2.  Proposed mechanism for the stabilization of nuclear receptor DNA binding via protein dimerization.

Authors:  G Jiang; U Lee; F M Sladek
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

3.  The extreme C terminus of progesterone receptor contains a transcriptional repressor domain that functions through a putative corepressor.

Authors:  J Xu; Z Nawaz; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  Transcriptional silencing by unliganded thyroid hormone receptor beta requires a soluble corepressor that interacts with the ligand-binding domain of the receptor.

Authors:  G X Tong; M Jeyakumar; M R Tanen; M K Bagchi
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

5.  Heterodimeric interaction between retinoid X receptor alpha and orphan nuclear receptor OR1 reveals dimerization-induced activation as a novel mechanism of nuclear receptor activation.

Authors:  F F Wiebel; J A Gustafsson
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

6.  Functional evidence for ligand-dependent dissociation of thyroid hormone and retinoic acid receptors from an inhibitory cellular factor.

Authors:  J Casanova; E Helmer; S Selmi-Ruby; J S Qi; M Au-Fliegner; V Desai-Yajnik; N Koudinova; F Yarm; B M Raaka; H H Samuels
Journal:  Mol Cell Biol       Date:  1994-09       Impact factor: 4.272

7.  DNA bending by thyroid hormone receptor: influence of half-site spacing and RXR.

Authors:  K Shulemovich; D D Dimaculangan; D Katz; M A Lazar
Journal:  Nucleic Acids Res       Date:  1995-03-11       Impact factor: 16.971

8.  Phosphorylation and intramolecular stabilization of the ligand binding domain in the nuclear receptor steroidogenic factor 1.

Authors:  Marion Desclozeaux; Irina N Krylova; Florence Horn; Robert J Fletterick; Holly A Ingraham
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

9.  The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation.

Authors:  M Au-Fliegner; E Helmer; J Casanova; B M Raaka; H H Samuels
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

10.  A shift in the ligand responsiveness of thyroid hormone receptor alpha induced by heterodimerization with retinoid X receptor alpha.

Authors:  F X Claret; T Antakly; M Karin; F Saatcioglu
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.